171 related articles for article (PubMed ID: 32550294)
1. Real-world questions and concerns about disease-modifying antirheumatic drugs (DMARDs): a retrospective analysis of questions to a medicine call center.
El Masri H; Hollingworth SA; van Driel M; Benham H; McGuire TM
BMC Rheumatol; 2020; 4():27. PubMed ID: 32550294
[TBL] [Abstract][Full Text] [Related]
2. Withdrawal and Misuse Concerns of Consumers regarding Opioid Analgesic and Anxiolytic, Hypnotic and Sedative Medicines.
McGuire TM; Sidhu K; van Driel ML; Hollingworth SA
Subst Use Misuse; 2020; 55(12):1980-1992. PubMed ID: 32613881
[TBL] [Abstract][Full Text] [Related]
3. Consumer concerns about paracetamol: a retrospective analysis of a medicines call centre.
Lau SM; McGuire TM; van Driel ML
BMJ Open; 2016 Jun; 6(6):e010860. PubMed ID: 27279476
[TBL] [Abstract][Full Text] [Related]
4. Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre.
Natari RB; Hollingworth SA; Clavarino AM; Dingle KD; McGuire TM
BMC Womens Health; 2021 Oct; 21(1):348. PubMed ID: 34607596
[TBL] [Abstract][Full Text] [Related]
5. Women's questions about medicines in pregnancy - An analysis of calls to an Australian national medicines call centre.
Pijpers EL; Kreijkamp-Kaspers S; McGuire TM; Deckx L; Brodribb W; van Driel ML
Aust N Z J Obstet Gynaecol; 2017 Jun; 57(3):334-341. PubMed ID: 27624748
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
7. What do consumers want to know about antibiotics? Analysis of a medicines call centre database.
Hawke KL; McGuire TM; Ranmuthugala G; van Driel ML
Fam Pract; 2016 Feb; 33(1):75-81. PubMed ID: 26502809
[TBL] [Abstract][Full Text] [Related]
8. The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice.
Roberts L; Tymms K; de Jager J; Littlejohn G; Griffiths H; Nicholls D; Bird P; Young J; Hill J; Zochling J
Int J Rheumatol; 2017; 2017():1201450. PubMed ID: 28630629
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
[TBL] [Abstract][Full Text] [Related]
11. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
[TBL] [Abstract][Full Text] [Related]
12. What do health consumers want to know about childhood vaccination? An evaluation of data from an Australian medicines call centre.
Mus M; Kreijkamp-Kaspers S; McGuire T; Deckx L; van Driel M
Aust N Z J Public Health; 2017 Feb; 41(1):74-79. PubMed ID: 27960227
[TBL] [Abstract][Full Text] [Related]
13. Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use.
Pache DM; Hollingworth SA; van Driel ML; McGuire TM
Res Social Adm Pharm; 2019 Apr; 15(4):440-447. PubMed ID: 29935855
[TBL] [Abstract][Full Text] [Related]
14. Children's medicine: What do consumers really want to know?
Crunkhorn C; van Driel M; Nguyen V; McGuire T
J Paediatr Child Health; 2017 Feb; 53(2):155-162. PubMed ID: 27662261
[TBL] [Abstract][Full Text] [Related]
15. How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study.
Jawad II; Nisar MK
Eur J Rheumatol; 2022 Apr; 9(2):100-103. PubMed ID: 35156631
[TBL] [Abstract][Full Text] [Related]
16. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
17. Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.
Min HK; Kim HR; Lee SH; Shin K; Kim HA; Park SH; Kwok SK
Clin Rheumatol; 2021 Aug; 40(8):3105-3113. PubMed ID: 33576925
[TBL] [Abstract][Full Text] [Related]
18. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
Lu CY; Williams KM; Day RO
Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
[TBL] [Abstract][Full Text] [Related]
19. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
20. Consumers' questions about antipsychotic medication: revealing safety concerns and the silent voices of young men.
Weersink RA; Taxis K; McGuire TM; van Driel ML
Soc Psychiatry Psychiatr Epidemiol; 2015 May; 50(5):725-33. PubMed ID: 25547083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
